



UNITED STATES PATENT AND TRADEMARK OFFICE



Bi Data Sheet

SERIAL NUMBER 09/293,533	FILING DATE 04/6/1999 RUL	CLASS 424
APPLICANTS MALAYA CHATTERJEE, LEXINGTON, KY; KENNETH A. FOERSTER, LEXINGTON, KY; SUNIL K. CHATTERJEE, LEXINGTON, KY;		
CONTINUING DATA ***** THIS APPLICATION IS A CONTINUATION OF 08/752,844 11/21/1996 F WHICH IS A CIP OF 08/591,196 01/16/1996 PAT 5,977,316 WHICH IS A CIP OF 08/372,676 01/17/1995 PAT 5,612,030		
FOREIGN APPLICATIONS *****		
IF REQUIRED, FOREIGN FILING LICENSE GRANTED 05/21/1999		** SMALL EN
Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 371(a-d) conditions met <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance	STATE OR COUNTRY KY	SH DP
Verified and Acknowledged: _____ Examiner's Signature Initials		
ADDRESS CATHERINE M POLIZZI MORRISON & FOERSTER LLP 755 PAGE MILL ROAD PALO ALTO, CA 94304-1018		
TITLE MONOCLONAL ANTIBODY 1A7 AND USE FOR THE TREATMENT OF CARCINOMA		
FILING FEE RECEIVED 452	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSITS No. _____ for following:	

SERIAL NUMBER	FILING DATE	CLASS	GROUP ART UNIT
09/293,533	04/15/95	435	1632

MALAYA CHATTERJEE, LEXINGTON, KY; KENNETH J. FOGG, LEXINGTON, KY;
SUNIL K. CHATTERJEE, LEXINGTON, KY.

****CONTINUING DOMESTIC DATA*******

VERIFIED THIS APPLN IS A CON OF 08/752,844 11/21/96 *pt*
WHICH IS A CIP OF 08/591,196 01/16/96
WHICH IS A CIP OF 08/372,676 01/17/9

****371 (NAT'L STAGE) DATA*******

VERIFIED

****FOREIGN APPLICATIONS*******

VERIFIED

REQUIRED, FOREIGN FILING LICENSE GRANTED 05/21/95 *SMALL E*

Priority claimed 119 (a-d) conditions met	<input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance	STATE OR COUNTRY	SHEETS DRAWING
and Acknowledged	<i>LM</i> Examiner's Initials	KY	24

ATHERINE M POLIZZI
ARRISON & FOERSTER LLP
5 PAGE MILL ROAD
DALTO CA 94304-1018

MONOCLONAL ANTIBODY IA7 AND USE FOR THE TREATMENT OF CARCINOMA AND
CELL CELL CARCINOMA

FEES ED	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT NO. _____ for the following	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fee <input type="checkbox"/> 1.17 Fee <input type="checkbox"/> 1.18 Fee <input type="checkbox"/> Other <input type="checkbox"/> Credit
452		